Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Adult Acute Megakaryoblastic Leukemia (M7): early-phase trial registry
A small indexed set (8 trials) with no open enrollment listed right now.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · none currently recruiting · #2,176 of 28,707 conditions by registered trial count
Adult Acute Megakaryoblastic Leukemia (M7): 8 US clinical trials tracked, none currently recruiting.
Adult Acute Megakaryoblastic Leukemia (M7) is the subject of 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.
Enrollment posture brief
Registry condition adult-acute-megakaryoblastic-leukemia-m7
OPEN 0 | RECR 0% | LATE 2 | EARLY 6 | RANK #2176 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Adult Acute Megakaryoblastic Leukemia (M7) has no open enrollment in this registry pull (8 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Adult Acute Megakaryoblastic Leukemia (M7) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Adult Acute Megakaryoblastic Leukemia (M7) is recruiting below its size-band peers.
0 of 8 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Adult Acute Megakaryoblastic Leukemia (M7) research.
National Cancer Institute (NCI) accounts for 6 of 8 trials (75%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Adult Acute Megakaryoblastic Leukemia (M7) trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 8 trials that report a genuine target (sentinel values excluded). 6 of those (75%) plan for fewer than 100 participants.
-
Adult Acute Megakaryoblastic Leukemia (M7) research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
8 total, page 1 of 1
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT00006363
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT00003190
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT00634244
XK469R in Treating Patients With Refractory Hematologic Cancer
National Cancer Institute (NCI)
NCT00095797
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
NCT00131989
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT00352365
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
Nohla Therapeutics
NCT01031368
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Case Comprehensive Cancer Center
NCT01127009
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Adult Acute Megakaryoblastic Leukemia (M7) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Adult Acute Megakaryoblastic Leukemia (M7) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Adult Acute Megakaryoblastic Leukemia (M7) page
8 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Adult Acute Megakaryoblastic Leukemia (M7) trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Adult Acute Megakaryoblastic Leukemia (M7) trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adult Acute Megakaryoblastic Leukemia (M7) condition card totals 8 registered trials; most-linked intervention cytarabine; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.